GlassScriptPhysician profile
Henry Guevara
NPI 1265843775
$13,684.88
in general payments reported to CMS, 2019-2025
39 companies · $2,944 in 2025
The $2,944 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,324 · 2022: $3,371 · 2023: $2,310 · 2024: $2,736 · 2025: $2,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,989.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,058.32 | 2021-2025 | Descovy, Yeztugo, Biktarvy |
| Astrazeneca Pharmaceuticals LP | $1,949.24 | 2021-2025 | Airsupra, Flumist Quadrivalent |
| Viiv Healthcare Company | $754.88 | 2022-2025 | Apretude |
| Merck Sharp & Dohme LLC | $600.75 | 2022-2025 | Pifeltro, Delstrigo, Isentress |
| Genzyme Corporation | $578.82 | 2023-2024 | |
| Genentech, INC. | $545.03 | 2021-2023 | Xolair, Xofluza |
| Horizon Therapeutics Plc | $439.87 | 2021-2023 | Krystexxa |
| Inspire Medical Systems, INC. | $386.77 | 2021-2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $377.89 | 2021-2025 | |
| Genentech USA, INC. | $335.73 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $302.00 | 2023 | Gammagard, Takhzyro, Cuvitru |
| Averitas Pharma INC. | $299.96 | 2025 | Qutenza |
| Biotronik Nro, INC. | $279.43 | 2024 | Prospera |
| Abbvie INC. | $254.64 | 2021-2022 | |
| Amgen INC. | $243.64 | 2023 | Repatha |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $231.65 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $230.32 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $217.37 | 2022 | |
| Teleflex LLC | $206.12 | 2024-2025 | Urolift, Barrigel |
| Teva Pharmaceuticals USA, INC. | $206.05 | 2021-2023 | |
| Abbott Laboratories | $204.44 | 2022-2024 | Proclaim |
| Abiomed | $137.48 | 2025 | |
| Mirum Pharmaceuticals, INC. | $128.32 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $124.72 | 2022 | |
| Boston Scientific Corporation | $124.17 | 2025 | Watchman Flx |
| Corium, LLC | $121.82 | 2023 | Azstarys |
| Tris Pharma INC | $118.70 | 2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Theratechnologies INC. | $118.63 | 2021 | |
| Scynexis, INC. | $116.15 | 2022 | |
| Kyowa Kirin, INC. | $115.36 | 2023 | |
| Sandoz INC. | $112.43 | 2025 | |
| Penumbra, INC. | $111.62 | 2023 | Indigo System |
| Regeneron Healthcare Solutions, INC. | $105.33 | 2025 | Dupixent |
| Amarin Pharma, INC. | $102.60 | 2025 | Vascepa |
| Janssen Products, LP | $99.00 | 2021 | |
| Bridgebio Pharma, INC. | $94.39 | 2025 | Attruby |
| Shield Therapeutics INC | $90.56 | 2022 | |
| Ethicon US, LLC | $81.18 | 2022 | |
| Biosense Webster, INC. | $79.50 | 2024 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Guevara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.